Literature DB >> 17233274

[Laryngeal tuberculosis. Incidence between 1994 and 2004].

J M Morales Puebla1, M Padilla Parrado, M A Díaz Sastre, J Chacón Martinez, J T Galán Morales, M O Lasso Luis, J A Jiménez Antolin, L M Menéndez Loras.   

Abstract

Tuberculosis is the chronic granulomatose most common infection of the larynx. It appears generally from pulmonary tuberculosis. It prevails in men. The most habitual symptomatology includes dysphony, odinophagy, referred otalgy and sometimes dispnea. The majority of patients use to have radiological pulmonary affectation to the diagnosis. The nodular exophitic or ulcerous lesions can be confused with carcinoma, therefore in these cases the anatomopathologic study is essential. The diagnosis is made with positive spit samples, specific characteristics of the thorax radiography and the positive biopsies of acid-alcohol resistant bacillus. We present the patients diagnosed with laryngeal tuberculosis in our hospital between 1994 and 2004. We describe the diagnostic procedures realised and the adopted therapeutic attitude in every case and results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17233274

Source DB:  PubMed          Journal:  An Otorrinolaringol Ibero Am        ISSN: 0303-8874


  3 in total

1.  Laryngeal mass.

Authors:  Sudesh Kumar; John Mathew; Rashid Al-Abri; Osama Ahmed; Pm Sapramadu
Journal:  Oman Med J       Date:  2011-07

2.  Infectious granulomatous laryngitis: a retrospective study of 24 cases.

Authors:  Leonardo Silva; Edward Damrose; Fernanda Bairão; Mayra L Della Nina; James C Junior; Henrique Olival Costa
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06       Impact factor: 2.503

3.  Factors Associated with Clinical and Topographical Features of Laryngeal Tuberculosis.

Authors:  João Gustavo Corrêa Reis; Clarissa Souza Mota Reis; Daniel César Silva da Costa; Márcia Mendonça Lucena; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhaes Oliveira; Valéria Cavalcanti Rolla; Fátima Conceição-Silva; Cláudia Maria Valete-Rosalino
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.